Maze Therapeutics Stock Forecast
NASDAQ: MAZEHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
After hours: 25.88 0.00%
MAZE analyst consensus
Consensus (13 analysts)
strong_buy
Avg. price target
$61.50+137.64%
- Strong buy 1
- Buy 12
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 13 Wall Street analysts covering Maze Therapeutics (2026-10-08), 13 rate the stock a buy or strong buy, 0 rate it a hold and 0 rate it a sell or strong sell, for a consensus rating of "strong_buy". The average 12-month price target is $61.50, with a high estimate of $110.00 and a low estimate of $46.00. The average target implies upside of 137.6% from the current price of $25.88.
The spread between the highest and lowest targets is 139.1%, a wide range that reflects significant disagreement among analysts. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for MAZE.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 1 | 8% |
| Buy | 12 | 92% |
| Hold | 0 | 0% |
| Sell | 0 | 0% |
| Strong sell | 0 | 0% |
Ratings as of 2026-10-08.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $46.00 | +77.74% |
| Average target | $61.50 | +137.64% |
| High target | $110.00 | +325.04% |